David Charles Rees

From Wikipedia, the free encyclopedia
  (Redirected from Draft:David Charles Rees)
Jump to navigation Jump to search
David Charles Rees
David Charles Rees
Born1958 (age 60–61)
Alma materUniversity of Southampton (BSc), University of Cambridge (PhD)
Known forAstex
AwardsRoyal Society of Chemistry, Malcolm Campbell Award 2007[1]
Scientific career
FieldsDrug discovery, Medicinal chemistry, Organic chemistry
InstitutionsAstex, AstraZeneca, Organon
ThesisA new approach to the synthesis of aspidosperma alkaloids using tricarbonylcyclohexadienylium iron intermediates[2]

David Charles Rees (born 1958) CChem, FRSC is a chemist whose main research interest is discovering new medicines.[3] He is Chief Scientific Officer at Astex Pharmaceuticals Cambridge UK,[4] a biotechnology company focussed on Fragment Based Drug Discovery. In 2003 David was hired by Astex to lead the chemistry team, and became Chief Scientific Officer in 2017.[5] Three anti-cancer agents were created in research involving David: ribociclib (Astex Novartis collaboration)[6] and erdafitinib (Astex Janssen collaboration)[7] and the anaesthetic agent sugammadex (Organon, Merck)[8] which had global sales of US$917 million in 2018.[9] David was President of the Organic Division from 2010 to 2013 of the Royal Society of Chemistry and was later elected as a Trustee of the RSC (2015-2019).[10]  He is a Director of Ashanti Development, a charity that promotes clean water and sanitation in Ghana.[11]


  1. ^ "BMCS Malcolm Campbell Award". Retrieved 2019-04-30.
  2. ^ "e-theses online service". Retrieved 2019-04-30.
  3. ^ "david rees - Google Scholar Citations". scholar.google.co.uk. Retrieved 2019-04-24.
  4. ^ "Astex – Oncology and CNS Drug Discovery & Development". Retrieved 2019-04-24.
  5. ^ "David Rees – Astex". Retrieved 2019-04-24.
  6. ^ Bickerton, Peggy. "Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval – Astex". Retrieved 2019-04-24.
  7. ^ webadmin. "Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval – Astex". Retrieved 2019-04-24.
  8. ^ Bom, Anton; Bradley, Mark; Cameron, Ken; Clark, John K.; Egmond, Jan van; Feilden, Helen; MacLean, Elizabeth J.; Muir, Alan W.; Palin, Ronald (2002). "A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host". Angewandte Chemie International Edition. 41 (2): 265–270. doi:10.1002/1521-3773(20020118)41:23.0.CO;2-Q. ISSN 1521-3773.
  9. ^ "Merck & Co., Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2018" (PDF).
  10. ^ "The Royal Society of Chemistry - our structure". www.rsc.org. Retrieved 2019-04-24.
  11. ^ "Our Team in the UK". Ashanti Development. Retrieved 2019-04-24.